Business Wire

Brand Jamaica to Shine at Penn Relays

27.4.2022 21:00:00 EEST | Business Wire | Press release

Share

Brand Jamaica will be highlighted at the 126th staging of the Penn Relays, which will be held from April 28-30, 2022, in Philadelphia, Pennsylvania. Five Jamaican manufacturers, Annilu Limited, Herboo, King’s Jamaican Health and Wellness, Bresheh, and Shavuot International, will interact with buyers, distributors, and retailers to promote their products with the aim of increasing Jamaica’s export sales.

The trade mission is taking place as part of the export development programme Export Max III, which is led by JAMPRO, the Jamaica Business Development Corporation (JBDC), and the Jamaica Manufacturers and Exporters Association (JMEA). The event will highlight the island’s diverse manufacturing sector, and the products that are available for export.

Jamaica’s Prime Minister, The Most Honourable Andrew Holness, and Minister of Industry, Investment, and Commerce, Senator the Honourable Aubyn Hill, will attend the Penn Relays. The event will feature a pavilion designed to house the Jamaican companies that will facilitate engagement with the over 100,000 patrons that are expected to attend the event. B2B (Business-to-Business) meetings will also take place to support the companies during the trade mission, as they look to build meaningful business relationships in the United States.

The Penn Relays are a great avenue for the promotion of Brand Jamaica because of its high profile as a major event and its historical connection with Jamaica, our athletes, and the diaspora,” explained Minister Hill. “The event therefore provides an opportunity for Jamaica to not only display amazing athletic performances, but to connect with the Jamaican Diaspora expected to attend the event, and will introduce products to buyers and retailers in that area who are interested in securing ethnic food and other goods for their markets.”

The government is also encouraging Jamaicans abroad to invest in agro-processing, skills training, and in logistics, particularly Jamaica’s Special Economic Zones.

Penn Relays trade mission critical part of developing Jamaica’s exports

The mission will be a critical step in Jamaica’s ongoing efforts to identify new export opportunities for manufacturers, establish Jamaica as a supplier of high-quality products, and to increase the international exposure of the country’s exporters. It is one of the island’s major trade executions since the COVID-19 pandemic and is expected to give a boost to the Export Max participants.

Diane Edwards, President of JAMPRO said, “This particular event is expected to generate significant leads for our exporters, and should help them to secure contractual arrangements with targeted US distributors. While this will not be the first time that Jamaica has had major activities at the Penn Relays, I believe that there are advantages to this edition, as this will be the first staging of the competition since the onset of the COVID-19 pandemic. There is also a joyous mood surrounding the event, as it falls in the same year of Jamaica's 60th Anniversary as an independent nation.”

Edwards insisted that the event will reinforce Jamaica’s image as a source of high-quality exports, and will serve many purposes for the manufacturers, as well as buyers. She said, “The companies that will be at the Penn Relays represent the high quality and diversity of Jamaican products, and this initiative will give them the opportunity to be on the world stage and reach new audiences. For the buyers, it will introduce them to Jamaican exporters, and will show them the vast range of products that we have to offer. We believe that this mission will be fruitful for all the participants and stakeholders, and we look forward to seeing the positive impact it will have on the Jamaican economy.”

The Jamaica Promotions Corporation’s (JAMPRO’s) mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tamica Parchment
Integrated Marketing Communications
tparchment@jamprocorp.com
Tele: 876-978-7755

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off

PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release

Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N

AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release

AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To

Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release

Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye